JACC:合并糖尿病的多血管病变患者选择CABG和PCI因人而异

2022-04-17 MedSci原创 MedSci原创

FREEDOM研究后续随访近8年的数据显示,对于合并糖尿病的多血管病变患者,冠状动脉旁路手术(CABG)优于经皮冠状动脉介入治疗(PCI)。

FREEDOM研究后续随访近8年的数据显示,对于合并糖尿病的多血管病变患者,冠状动脉旁路手术(CABG)优于经皮冠状动脉介入治疗(PCI)。

目前,对于这类患者,指南已经明显地倾向于CABG而不是使用药物洗脱支架(DES)进行PCI,但是一直缺乏长期随访的数据,直到这项FREEDOM研究中位随访7.5年的生存数据发表。

值得注意的是,该研究数据显示,与PCI相比,CABG带给65岁以下的患者和曾经吸烟的患者的生存获益尤其显着。CABG和PCI对于65岁以上的老年患者和从不吸烟者的生存获益相似。尽管如此,但个别患者在许多特征上有所不同,会影响治疗的好处和坏处。

FREEDOM评分是在8个患者特征和吸烟-治疗互动的基础上,预测CABG与PCI的不同结果。为了评估5年主要不良心血管事件(MACE)模型在SYNTAX和BEST试验中预测CABG与PCI治疗效益的能力,来自荷兰阿姆斯特丹大学医学中心心脏中心的专家开展了相关研究,结果发表在JACC杂志上。

本研究纳入了702名糖尿病和MVD患者,以反映FREEDOM参与者的情况。通过C-指数评估鉴别力,并通过校准图评估PCI和CABG两组的校准情况。评估了FREEDOM评分预测CABG与PCI治疗效益的能力。

总的来说,与PCI相比,CABG与较低的5年MACE率有关(12.4% vs 20.3%;对数rank P = 0.021),而不考虑吸烟史(Pinteraction = 0.975)。鉴别力和校正力在PCI组都是有帮助的(C-指数=0.69;斜率=0.96,截距=-0.24),但在CABG组是中等的(C-指数=0.61;斜率=0.61;截距=-0.53)。可见,FREEDOM评分显示了治疗效果的一定异质性。

FREEDOM评分可以识别出CABG与PCI的5年MACE的治疗获益的一定异质性。在进行进一步的前瞻性验证之前,在糖尿病和MVD患者中使用FREEDOM评分时应考虑这些结果。

参考文献:

External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI. J Am Coll Cardiol. 2022 Apr, 79 (15) 1458–1473

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1855056, encodeId=e7db1855056b5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 08 02:13:23 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644939, encodeId=7dd21644939e8, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Dec 01 04:13:23 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211870, encodeId=ee9a12118e09d, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sun Apr 17 12:20:52 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326947, encodeId=8938132694e30, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 18 06:13:23 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391118, encodeId=09081391118e2, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Apr 18 06:13:23 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2022-12-08 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1855056, encodeId=e7db1855056b5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 08 02:13:23 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644939, encodeId=7dd21644939e8, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Dec 01 04:13:23 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211870, encodeId=ee9a12118e09d, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sun Apr 17 12:20:52 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326947, encodeId=8938132694e30, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 18 06:13:23 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391118, encodeId=09081391118e2, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Apr 18 06:13:23 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1855056, encodeId=e7db1855056b5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 08 02:13:23 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644939, encodeId=7dd21644939e8, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Dec 01 04:13:23 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211870, encodeId=ee9a12118e09d, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sun Apr 17 12:20:52 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326947, encodeId=8938132694e30, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 18 06:13:23 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391118, encodeId=09081391118e2, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Apr 18 06:13:23 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2022-04-17 屋顶瞄爱赏月

    学习学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1855056, encodeId=e7db1855056b5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 08 02:13:23 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644939, encodeId=7dd21644939e8, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Dec 01 04:13:23 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211870, encodeId=ee9a12118e09d, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sun Apr 17 12:20:52 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326947, encodeId=8938132694e30, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 18 06:13:23 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391118, encodeId=09081391118e2, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Apr 18 06:13:23 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1855056, encodeId=e7db1855056b5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 08 02:13:23 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644939, encodeId=7dd21644939e8, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Dec 01 04:13:23 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211870, encodeId=ee9a12118e09d, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sun Apr 17 12:20:52 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326947, encodeId=8938132694e30, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 18 06:13:23 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391118, encodeId=09081391118e2, content=<a href='/topic/show?id=6d0689e19f0' target=_blank style='color:#2F92EE;'>#血管病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89719, encryptionId=6d0689e19f0, topicName=血管病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Mon Apr 18 06:13:23 CST 2022, time=2022-04-18, status=1, ipAttribution=)]

相关资讯

从RAR介导的信号传递角度 探讨糖尿病心肌病成因

 糖尿病心肌病(DCM)是由糖尿病引起的、以左室舒张和(或)收缩功能障碍为表现的心肌病变,且与高血压性心脏病、冠状动脉粥样硬化性心脏病、心脏瓣膜病及其他心脏病变无关。该疾病在代谢紊乱及微血管病变的基础上引发心肌广泛灶性坏死,出现亚临床心功能异常,最终进展为心力衰竭、心律失常及心源性休克,重症患者甚至发生猝死。   潘静, 美国心脏学会(AHA)、美国糖尿病学会(ADA)会员,美国得克萨斯A&

Cell Death Dis:HMGA1通过抑制自噬加重糖尿病心肌病患者的心功能不全

流行病学研究表明,糖尿病(DM)与心力衰竭(HF)密切相关;在2型糖尿病的患者人群中,心力衰竭比心肌梗塞更为常见。结构转录因子HMGA1,对糖尿病心肌病的心脏重塑的影响尚不明确。

JAHA:Sirtuin 3通过调节TIGAR和心肌细胞代谢缓解糖尿病心肌病

SIRT3可能是糖尿病异常能量代谢的新靶点

Diabetes:MICU1通过线粒体Ca2+依赖的抗氧化反应缓解糖尿病心肌病!

总的来说,该研究结果首次提供了直接证据证实上调MICU1可以保护db/db小鼠的心脏功能,这表明增加MICU1的表达或活性可能是改善心肌病糖尿病的一种药物治疗方法。

拓展阅读

JCN:移动健康应用于经皮冠状动脉介入治疗后患者心脏康复的可行性及效果

这项基于理论的移动健康CR研究是为满足经皮冠状动脉介入治疗后患者的护理需求而制定的方案。

NEJM:在未服用心绞痛药物的稳定型心绞痛患者,单独接受PCI治疗能有效缓解心绞痛

在接受少量或未接受抗心绞痛药物治疗且有缺血客观证据的稳定型心绞痛患者中,PCI术后心绞痛症状评分低于安慰剂术后,表明心绞痛患者的健康状况更好。

JACC:经皮冠状动脉介入治疗术后抗血小板治疗的方案及时长

与DAPT治疗≥3个月相比,DAPT治疗1个月的NACE或MACE事件风险相近,但MCB发生率更低

European Radiology:纳入这一参数的CCTA评分系统可实现PCI治疗效果的预测

经皮冠状动脉介入(PCI)目前,冠状动脉计算机断层扫描(CCTA)是经皮冠状动脉介入(PCI)术前评估操作难度最重要的手段。

EHJ:三血管或左主干患者手术怎么选?选PCI还是CABG还真有讲究!

在3VD和/或LMCAD患者中,MAG可能是更理想的CABG配置,以实现比PCI更低的长期全因死亡率。